These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31626145)

  • 1. Outcomes of pathologically localized high-grade prostate cancer treated with radical prostatectomy.
    Heo JE; Park JS; Lee JS; Kim J; Jang WS; Rha KH; Choi YD; Hong SJ; Ham WS
    Medicine (Baltimore); 2019 Oct; 98(42):e17627. PubMed ID: 31626145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer.
    Ham WS; Chalfin HJ; Feng Z; Trock BJ; Epstein JI; Cheung C; Humphreys E; Partin AW; Han M
    Eur Urol; 2017 Jun; 71(6):907-912. PubMed ID: 27876305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radical prostatectomy in Denmark: Survival analysis and temporal trends in clinicopathological parameters with up to 20 years of follow-up.
    Heering M; Berg KD; Brasso K; Iversen P; Røder MA
    Surg Oncol; 2017 Mar; 26(1):21-27. PubMed ID: 28317581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer.
    Özsoy M; D'Andrea D; Moschini M; Foerster B; Abufaraj M; Mathieu R; Briganti A; Karakiewicz PI; Roupret M; Seitz C; Czech AK; Susani M; Shariat SF
    Urol Oncol; 2018 Apr; 36(4):158.e1-158.e6. PubMed ID: 29288003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postoperative biochemical recurrence of pathologically localized high-grade prostate cancer in adjuvant treatment-naïve patients.
    Heo JE; Park JS; Lee JS; Kim J; Jang WS; Cho NH; Rha KH; Choi YD; Hong SJ; Ham WS
    J Cancer Res Clin Oncol; 2020 Jan; 146(1):221-227. PubMed ID: 31612318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Preoperative Risk Group Stratification on Oncologic Outcomes of Patients with Adverse Pathologic Findings at Radical Prostatectomy.
    Jang WS; Kim LH; Yoon CY; Rha KH; Choi YD; Hong SJ; Ham WS
    PLoS One; 2016; 11(10):e0164497. PubMed ID: 27716842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential prognostic impact of different Gleason patterns in grade group 4 in radical prostatectomy specimens.
    Mori K; Sharma V; Comperat EM; Sato S; Laukhtina E; Schuettfort VM; Pradere B; Parizi MK; Karakiewicz PI; Egawa S; Tilki D; Boorjian SA; Shariat SF
    Eur J Surg Oncol; 2021 May; 47(5):1172-1178. PubMed ID: 33371950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic impact of downgrading and upgrading from biopsy to radical prostatectomy among men with Gleason score 7 prostate cancer.
    Jang WS; Koh DH; Kim J; Lee JS; Chung DY; Ham WS; Rha KH; Choi YD
    Prostate; 2019 Dec; 79(16):1805-1810. PubMed ID: 31483062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of surgical margin status on prostate-cancer-specific mortality.
    Chalfin HJ; Dinizo M; Trock BJ; Feng Z; Partin AW; Walsh PC; Humphreys E; Han M
    BJU Int; 2012 Dec; 110(11):1684-9. PubMed ID: 22788795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interval to biochemical recurrence following radical prostatectomy does not affect survival in men with low-risk prostate cancer.
    Bolton DM; Ta A; Bagnato M; Muller D; Lawrentschuk NL; Severi G; Syme RR; Giles GG
    World J Urol; 2014 Apr; 32(2):431-5. PubMed ID: 23824175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.
    Brockman JA; Alanee S; Vickers AJ; Scardino PT; Wood DP; Kibel AS; Lin DW; Bianco FJ; Rabah DM; Klein EA; Ciezki JP; Gao T; Kattan MW; Stephenson AJ
    Eur Urol; 2015 Jun; 67(6):1160-1167. PubMed ID: 25301759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrence.
    Pompe RS; Gild P; Karakiewicz PI; Bock LP; Schlomm T; Steuber T; Graefen M; Huland H; Tian Z; Tilki D
    Prostate; 2018 Jun; 78(9):676-681. PubMed ID: 29570821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
    Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic role of tertiary Gleason pattern 5 in a contemporary grading system for prostate cancer.
    Jang WS; Yoon CY; Kim MS; Kang DH; Kang YJ; Jeong WS; Abalajon MJ; Ham WS; Choi YD
    Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):93-98. PubMed ID: 27845330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy.
    Fajkovic H; Mathieu R; Lucca I; Hiess M; Hübner N; Al Hussein Al Awamlh B; Lee R; Briganti A; Karakiewicz P; Lotan Y; Roupret M; Rink M; Kluth L; Loidl W; Seitz C; Klatte T; Kramer G; Susani M; Shariat SF
    Urol Oncol; 2016 May; 34(5):233.e1-6. PubMed ID: 26973136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short (≤ 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy.
    Shikanov S; Marchetti P; Desai V; Razmaria A; Antic T; Al-Ahmadie H; Zagaja G; Eggener S; Brendler C; Shalhav A
    BJU Int; 2013 Apr; 111(4):559-63. PubMed ID: 22759270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The New Prostate Cancer Grading System Does Not Improve Prediction of Clinical Recurrence After Radical Prostatectomy: Results of a Large, Two-Center Validation Study.
    Dell'Oglio P; Karnes RJ; Gandaglia G; Fossati N; Stabile A; Moschini M; Cucchiara V; Zaffuto E; Karakiewicz PI; Suardi N; Montorsi F; Briganti A
    Prostate; 2017 Feb; 77(3):263-273. PubMed ID: 27753114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The CPC Risk Calculator: A New App to Predict Prostate-specific Antigen Recurrence During Follow-up After Radical Prostatectomy.
    Røder MA; Berg KD; Loft MD; Thomsen FB; Ferrari M; Kurbegovic S; Rytgaard HC; Gruschy L; Brasso K; Gerds TA; Kjær A; Brooks JD; Iversen P
    Eur Urol Focus; 2018 Apr; 4(3):360-368. PubMed ID: 28753827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns and predictors of early biochemical recurrence after radical prostatectomy and adjuvant radiation therapy in men with pT3N0 prostate cancer: implications for multimodal therapies.
    Briganti A; Joniau S; Gandaglia G; Cozzarini C; Sun M; Tombal B; Haustermans K; Hinkelbein W; Shariat SF; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):960-7. PubMed ID: 24351411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is More Always Better? An Assessment of the Impact of Lymph Node Yield on Outcome for Clinically Localized Prostate Cancer with Low/Intermediate Risk Pathology (pT2-3a/pN0) Managed with Prostatectomy Alone.
    Seyedin SN; Mitchell DL; Mott SL; Russo JK; Tracy CR; Snow AN; Parkhurst JR; Smith MC; Buatti JM; Watkins JM
    Pathol Oncol Res; 2019 Jan; 25(1):209-215. PubMed ID: 29079967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.